Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005922
Status:
COMPLETED
Last Update Posted:
2013-09-24
First Post:
2000-06-22
Brief Title:
Conditioning the Placebo Effect and Psoriasis
Sponsor:
University of Rochester
Organization:
University of Rochester
Study Overview
Official Title:
Role of Conditioning in the Pharmacotherapy of Psoriasis
Status:
COMPLETED
Status Verified Date:
2013-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study uses the psychological principle known as classical conditioning to try to improve the standard treatment of psoriasis Classical conditioning is a process of behavioral modification in which a person learns to connect a certain response-in this case improvement of psoriasis-with a new action or stimulus-in this case application of an inactive cream The goal of this study is to show that people with psoriasis who are maintained on corticosteroid cream part of the time and an inactive placebo cream at other times show a lower incidence of relapse and a reduced severity of psoriasis that patients treated with that same reduced amount of medication administered all the time
Detailed Description:
The lack of scientific attention devoted to the placebo effect as a phenomenon in its own right probably reflects the paucity of theoretical positions within which to organize the existing data and design new research This research addresses the clinical significance of behavior-immune system interactions
This study will capitalize on conditioned immunosuppressive responses to reduce the cumulative amount of corticosteroid medication used in the treatment of psoriasis We will continue to treat patients with steroid but will shift experimental patients from their current schedule of continuous reinforcement active drug whenever medication is applied to a partial schedule of reinforcement active drug a percentage of the time and placebo alone at other times To equate amount of medication we will treat another group of patients with a reduced dose of steroid in a standard treatment regimen continuous schedule of reinforcement
We hypothesize that holding cumulative dose constant a partial schedule of reinforcement will enable patients to be maintained on lower cumulative amounts of corticosteroid than patients treated under a continuous schedule of active drug This is the first attempt to adopt conditioning principles and use schedules of reinforcement to design regimens of drug therapy If proven effective this new approach to pharmacotherapy and placebo effects is likely to stimulate new interdisciplinary research in neuropharmacology and behavioral pharmacology for the treatment of autoimmune disorders and a variety of other chronic diseases
This study will capitalize on conditioned immunosuppressive responses to reduce the cumulative amount of corticosteroid medication used in the treatment of psoriasis We will continue to treat patients with steroid but will shift experimental patients from their current schedule of continuous reinforcement active drug whenever medication is applied to a partial schedule of reinforcement active drug a percentage of the time and placebo alone at other times To equate amount of medication we will treat another group of patients with a reduced dose of steroid in a standard treatment regimen continuous schedule of reinforcement
We hypothesize that holding cumulative dose constant a partial schedule of reinforcement will enable patients to be maintained on lower cumulative amounts of corticosteroid than patients treated under a continuous schedule of active drug This is the first attempt to adopt conditioning principles and use schedules of reinforcement to design regimens of drug therapy If proven effective this new approach to pharmacotherapy and placebo effects is likely to stimulate new interdisciplinary research in neuropharmacology and behavioral pharmacology for the treatment of autoimmune disorders and a variety of other chronic diseases
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NIAMS-051 | US NIH GrantContract | None | httpsreporternihgovquickSearchR01AR046825 |
| R01AR046825 | NIH | None | None |